{"gene":"ANKRD1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2009,"finding":"ANKRD1/CARP physically interacts with the N2A domain of titin/connectin and with myopalladin in cardiomyocytes; HCM-associated missense mutations (Pro52Ala, Thr123Met, Ile280Val) increase binding of CARP to both titin/connectin and myopalladin, and cause abnormal localization of CARP in neonatal rat cardiomyocytes.","method":"Co-immunoprecipitation, cellular localization in neonatal rat cardiomyocytes with myc-tagged mutant CARP","journal":"Journal of the American College of Cardiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with functional follow-up (localization assay), single lab but two orthogonal methods","pmids":["19608031"],"is_preprint":false},{"year":2009,"finding":"DCM-associated ANKRD1 mutations (M184I and P105S) abolish or reduce binding of CARP to Talin-1, and M184I also disrupts binding to FHL2, as measured by yeast two-hybrid; these mutations alter stretch-mediated gene expression without changing intracellular localization of mutant CARP proteins.","method":"Yeast two-hybrid, quantitative real-time RT-PCR of stretch-induced gene expression in myoblastoid cell lines","journal":"Journal of the American College of Cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional stretch assay, single lab","pmids":["19608030"],"is_preprint":false},{"year":2009,"finding":"DCM-associated ANKRD1 mutant proteins (sequenced from 231 DCM patients) show significantly reduced transcriptional repressor activity in reporter gene assays and greater phenylephrine-induced hypertrophy when expressed in neonatal rat cardiomyocytes, indicating loss-of-function for transcriptional repression.","method":"Reporter gene assay (transfection in neonatal rat cardiomyocytes), hypertrophy assay","journal":"European heart journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter gene assay plus hypertrophy phenotype, single lab, two orthogonal readouts","pmids":["19525294"],"is_preprint":false},{"year":2008,"finding":"A TAPVR-associated missense mutation in ANKRD1 enhances protein stability (resistance to calpain-mediated degradation) and increases its transcriptional repression activity on the ANF promoter.","method":"In vitro calpain-mediated degradation assay, reporter gene analysis in transfected HeLa cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro degradation assay combined with reporter gene assay, single lab, two orthogonal methods","pmids":["18273862"],"is_preprint":false},{"year":2009,"finding":"ANKRD1 protein levels are regulated by 26S proteasome-mediated degradation; a PEST motif within ANKRD1 is critical for this degradation, though other degrons also contribute.","method":"Proteasome inhibitor treatment, PEST motif mutagenesis, pulse-chase analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct mutagenesis of degradation motif with proteasome inhibitor validation, single lab","pmids":["19589340"],"is_preprint":false},{"year":2010,"finding":"ANKRD1/CARP physically interacts with the tumor suppressor p53 both in vivo and in vitro, and functions as a transcriptional co-activator that moderately upregulates p53 activity; p53 in turn acts as an upstream effector that upregulates the proximal ANKRD1 promoter.","method":"Protein array, co-immunoprecipitation (in vivo and in vitro), reporter gene assay (promoter activity)","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein array identification confirmed by Co-IP and reporter assay, single lab, multiple orthogonal methods","pmids":["20599664"],"is_preprint":false},{"year":2015,"finding":"ANKRD1 is part of a sarcomeric signaling complex with ERK1/2 and GATA4 in neonatal rat ventricular myocytes; phenylephrine treatment induces ERK1/2 and GATA4 phosphorylation and nuclear translocation of the ANKRD1/ERK/GATA4 complex. Knockdown of Ankrd1 attenuates ERK1/2 and GATA4 phosphorylation and prevents PE-induced cardiomyocyte growth. Ankrd1 null mice fail to develop PE-induced cardiac hypertrophy but develop normal hypertrophy in response to pressure overload (TAC).","method":"Co-immunoprecipitation, siRNA knockdown, adrenergic agonist stimulation assays, Ankrd1 knockout mouse with PE infusion and TAC","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro siRNA knockdown with phosphorylation readout, in vivo KO mouse with two distinct hypertrophic stimuli, multiple orthogonal methods across in vitro and in vivo models","pmids":["25770146"],"is_preprint":false},{"year":2012,"finding":"GATA4 acts upstream of ANKRD1 by activating the proximal CARP/ANKRD1 promoter; CARP/ANKRD1 knockdown inhibits myofilament gene transcription and induces sarcomere disarray; CARP depletion abolishes GATA4 overexpression-mediated rescue of doxorubicin-induced sarcomere disorganization, demonstrating co-dependent roles for GATA4 and CARP in sarcomere gene expression and structural maintenance.","method":"Co-transfection reporter assay, siRNA knockdown, adenoviral overexpression, doxorubicin treatment in cardiomyocytes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay for promoter activation, siRNA knockdown with defined sarcomere phenotype, epistasis via rescue experiment, single lab","pmids":["22532871"],"is_preprint":false},{"year":2005,"finding":"ANKRD1 selectively binds cardiac calsequestrin-2 (CASQ2) in heart extracts, confirmed by pull-down, blot-overlay, and co-immunoprecipitation; five non-overlapping binding sequences for CASQ2 were mapped on ANKRD1, and three ANKRD1-binding peptides were identified on CASQ2; endogenous ANKRD1 and CASQ2 are co-enriched in cardiac Purkinje cells.","method":"Pull-down from heart tissue extracts, blot-overlay assay, co-immunoprecipitation, peptide mapping, immunohistochemistry","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — three orthogonal binding assays (pull-down, blot-overlay, Co-IP) plus peptide epitope mapping, single lab","pmids":["15698842"],"is_preprint":false},{"year":2015,"finding":"ANKRD1 binds the p50 subunit of NF-κB (confirmed by co-immunoprecipitation) and inhibits TNFα-induced NF-κB transcriptional activity in C2C12 myoblasts; ANKRD1 also binds chromatin at an NF-κB binding site in the ANKRD2 promoter in a NF-κB-dependent manner, providing feedback inhibition of NF-κB signaling.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression, NF-κB reporter assay, ChIP assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus functional reporter assay, single lab, multiple methods","pmids":["26102030"],"is_preprint":false},{"year":2014,"finding":"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site; ANKRD1 associates with nucleolin (by yeast two-hybrid and co-immunoprecipitation); deletion of Ankrd1 elevates MMP13 mRNA and protein; ChIP shows greater c-Jun binding to the MMP13 AP-1 site in Ankrd1-null fibroblasts; ANKRD1 also represses MMP10.","method":"Yeast two-hybrid, co-immunoprecipitation, EMSA, ChIP, promoter activity assay, qPCR, protein analysis in Ankrd1-/- mice","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid, Co-IP, EMSA, ChIP, and KO mouse validation all converge on same mechanism, single lab but five orthogonal methods","pmids":["24515436"],"is_preprint":false},{"year":2014,"finding":"Global deletion of Ankrd1 impairs dermal fibroblast spreading and migration on collagen and fibronectin, abolishes contraction of 3D collagen gels, and delays wound closure in vivo; adenoviral re-expression of ANKRD1 restores collagen gel contraction, actin fiber organization, and rescues ischemic skin flap necrosis.","method":"Global Ankrd1 KO mouse (Sox2-cre), fibroblast migration and spreading assays, 3D collagen gel contraction, adenoviral reconstitution, excisional wound and ischemic flap models","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotypes validated by adenoviral rescue both in vitro and in vivo","pmids":["25452119"],"is_preprint":false},{"year":2013,"finding":"ANKRD1 binds the androgen receptor (AR) (by co-immunoprecipitation) and acts as a transcriptional repressor of AR-mediated gene expression; testosterone reduces Ankrd1 mRNA ~50% in L6.AR myoblasts; Ankrd1 overexpression blocks testosterone-induced reporter gene activity and modulates expression of MEF2d, myogenin, p21, and TnnI1 downstream of AR.","method":"Co-immunoprecipitation, reporter gene assay (ARE-Luc, MAFbx-Luc), qPCR of testosterone-regulated genes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirmed physical interaction, reporter assay confirms functional repression, single lab","pmids":["23811403"],"is_preprint":false},{"year":2013,"finding":"HCM-associated ANKRD1 mutations have distinct functional consequences in engineered heart tissues: T123M produces a gain-of-function with higher contractile force and velocities and correct sarcomere incorporation; P52A and I280V are highly unstable, excluded from the sarcomere, and rapidly degraded by the proteasome; proteasome inhibition stabilizes P52A and I280V, enabling sarcomere incorporation, and I280V then produces prolonged relaxation (dominant-negative effect).","method":"Adeno-associated virus gene transfer into engineered heart tissues, contractile parameter analysis, proteasome inhibitor (epoxomicin) treatment","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay in engineered tissue with pharmacological manipulation, single lab","pmids":["23572067"],"is_preprint":false},{"year":2011,"finding":"ANKRD1 interacts with desmin in smooth muscle cells; siRNA knockdown of desmin upregulates Ankrd1 expression via activation of the Akt/IKKα/IκBα/NF-κB signaling cascade; NF-κB directly binds the Ankrd1 promoter to drive its transcription as shown by luciferase reporter assay.","method":"siRNA knockdown, Western blot for pathway phosphorylation, pharmacological inhibitors of Akt/IKK/NF-κB, siRNA against p50/p65, luciferase reporter assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic epistasis combined with reporter assay, single lab, multiple orthogonal methods","pmids":["22085644"],"is_preprint":false},{"year":2017,"finding":"ANKRD1 is a YAP1 target gene induced by RASSF1A co-expression; ANKRD1 physically interacts with p53, induces TP53, BAX, and CDKN1A expression, destabilizes MDM2, and reduces cancer cell colony formation in a p53-dependent manner.","method":"Reporter/expression assays, co-immunoprecipitation (ANKRD1–p53 interaction), colony formation assay, gene expression analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirms protein interaction; functional epistasis with p53 shown by colony assay; single lab","pmids":["29179447"],"is_preprint":false},{"year":2015,"finding":"ERK5, but not ERK1/2, induces Ankrd1 expression in PC12 adrenal cells; Ankrd1 stabilizes tyrosine hydroxylase (TH) protein (without changing TH mRNA), reduces TH ubiquitination, and is required for catecholamine biosynthesis during neural differentiation.","method":"Microarray with ERK5/ERK1/2-specific inhibitors, siRNA knockdown, ubiquitination assay, catecholamine biosynthesis measurement","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — microarray target identification confirmed by siRNA knockdown with ubiquitination and biochemical readouts, single lab","pmids":["26739108"],"is_preprint":false},{"year":2020,"finding":"ANKRD1 overexpression in mouse myocardium causes sinus venosus defect during development through impaired remodeling; adult transgenic hearts develop progressive diastolic dysfunction with impaired lusitropism, sarcomere disassembly, and altered titin gene expression; embryonic overexpression transiently activates GATA4-Nkx2.5 transcription. ANKRD1 has dynamic nucleo-sarcomeric localization in developing cardiomyocytes.","method":"Transgenic mouse overexpression (myocardium-specific), histological analysis, hemodynamic measurements, myofibrillar functional assays, transcriptional profiling","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic mouse model with histological, hemodynamic, and molecular readouts across developmental and adult timepoints, single lab but multiple orthogonal methods","pmids":["31688894"],"is_preprint":false},{"year":2024,"finding":"Nuclear AGO2 activates ANKRD1 transcription in failing cardiomyocytes; nuclear ANKRD1 overexpression exacerbates cardiac remodeling by inducing MYH7 (pathological), while cytosolic ANKRD1 appears cardioprotective; ivermectin and an ANKRD1 nuclear localization signal mimetic peptide (ANPep) block ANKRD1 nuclear import and improve cardiac function in TAC-induced heart failure mice.","method":"Recombinant AAV9 overexpression (nuclear vs. cytosolic AGO2/ANKRD1), TAC mouse model, mechanistic reporter assays, pharmacological intervention with ivermectin and ANPep","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — compartment-specific AAV overexpression with functional in vivo cardiac readouts and pharmacological rescue, single lab","pmids":["38475992"],"is_preprint":false},{"year":2024,"finding":"ANKRD1 promotes ACSL3 degradation by facilitating TRIM25-mediated K63-linked ubiquitination of ACSL3, thereby amplifying lipid peroxidation and ferroptosis during renal ischemia-reperfusion injury; knockdown of ANKRD1 in mouse kidneys (rAAV9) reduces renal damage and ferroptosis.","method":"Immunoprecipitation-mass spectrometry (interactome), Co-IP, proximity ligation assay, ubiquitination assay, rAAV9-mediated knockdown in vivo, cell viability and lipid peroxidation assays","journal":"Clinical and translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — IP-MS interactome followed by Co-IP, proximity ligation, and ubiquitination assay, validated in vivo with rAAV knockdown, single lab but multiple orthogonal methods","pmids":["39285846"],"is_preprint":false},{"year":2024,"finding":"ANKRD1 is a mesenchymal-specific transcriptional coregulator under direct androgen receptor (AR) negative control; ANKRD1 drives cancer-associated fibroblast (CAF) activation by binding regulatory regions of myofibroblast CAF effector genes and promoting c-JUN and FOS (AP-1) association; targeting ANKRD1 disrupts AP-1 complex formation and reverses CAF activation in an orthotopic skin cancer model.","method":"Chromatin immunoprecipitation (ChIP), Co-IP for AP-1 complex, siRNA/knockdown, AR overexpression/loss, orthotopic mouse tumor model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP confirms ANKRD1 binding to target gene regulatory regions, Co-IP shows AP-1 complex disruption, in vivo orthotopic model validates functional consequence, multiple orthogonal methods","pmids":["38310103"],"is_preprint":false},{"year":2024,"finding":"ANKRD1 knockdown in C2C12 myoblasts decreases proliferation but increases differentiation; mechanistically, Ankrd1 represses the Itga6 promoter (shown by dual-luciferase reporter assay), and its knockdown upregulates ITGA6, leading to enhanced FAK phosphorylation and activation of the FAK/Rho-GTPase/F-actin pathway.","method":"siRNA knockdown, overexpression, RNA-seq, dual-luciferase reporter assay for Itga6 promoter, FAK phosphorylation assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay confirms transcriptional regulation of Itga6, combined with RNA-seq and signaling pathway analysis, single lab","pmids":["38988048"],"is_preprint":false},{"year":2024,"finding":"ANKRD1 promotes lamellipodia formation and cell motility in clear cell renal cell carcinoma cells; ANKRD1 colocalizes with F-actin and talin-1 in lamellipodia upon phorbol ester stimulation; ANKRD1 depletion represses talin-1-mediated integrin pathway activation and reduces lamellipodia formation.","method":"siRNA knockdown, overexpression, immunofluorescence co-localization, migration assay, integrin pathway activation analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-localization by immunofluorescence plus knockdown migration phenotype, single lab","pmids":["40362467"],"is_preprint":false},{"year":2024,"finding":"RBMS1 RNA-binding protein stabilizes ANKRD1 mRNA during early senescence; RBMS1 relocates from nucleus to cytoplasm after etoposide treatment, binds a region proximal to the ANKRD1 coding sequence, and silencing RBMS1 reduces while overexpressing RBMS1 enhances ANKRD1 mRNA half-life.","method":"Antisense oligomer pulldown with mass spectrometry, ribonucleoprotein immunoprecipitation, mRNA half-life measurement, RBMS1 siRNA and overexpression, heterologous reporter assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ASO pulldown plus RIP confirms RBMS1 binding; functional mRNA stability shown by half-life assay and reporter, single lab, multiple orthogonal methods","pmids":["38769646"],"is_preprint":false},{"year":2024,"finding":"Ankrd1 regulates cardiomyocyte cell cycle and cardiac regeneration, at least in part through cyclin D1; cardiomyocyte-specific Ankrd1 knockdown inhibits myocardial regeneration after apical resection in neonatal mice, and cardiomyocyte-specific overexpression promotes cardiac repair after adult myocardial infarction.","method":"Ankrd1 cardiomyocyte-specific knockdown and overexpression, neonatal apical resection model, adult MI model, cyclin D1 mechanistic analysis","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cardiomyocyte-specific genetic manipulation in two distinct injury models with cyclin D1 mechanistic link, single lab","pmids":["39299480"],"is_preprint":false},{"year":2012,"finding":"The 26S proteasome is the dominant regulator of ANKRD1/CARP degradation in both adult rat ventricular myocytes and human microvascular endothelial cells; ANKRD1/CARP half-life is significantly longer in cardiomyocytes (hours) than in endothelial cells (minutes), and higher endothelial cell density decreases ANKRD1 protein without affecting mRNA.","method":"Proteasome inhibitor treatment, protein half-life measurement (pulse-chase), cell density manipulation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological proteasome inhibition combined with protein half-life analysis in two cell types, single lab","pmids":["22892129"],"is_preprint":false},{"year":2023,"finding":"ANKRD1 regulates ferroptosis in HK-2 renal tubular cells through the p53/SLC7A11 signaling pathway; silencing or overexpression of ANKRD1 modulates SLC7A11 and GPX4 expression and the extent of ferroptosis induced by CaOx crystals.","method":"Lentiviral ANKRD1 silencing and overexpression, Western blot for ferroptosis markers (SLC7A11, GPX4, ACSL4), Fe2+ accumulation assay","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, gain- and loss-of-function with Western blot readout only, no direct epistasis experiment","pmids":["36907445"],"is_preprint":false},{"year":2023,"finding":"ANKRD1 promotes osteogenic differentiation of BMSCs by modulating CAV3 expression through reduction of CAV3 ubiquitination, thereby activating Wnt/β-catenin signaling; CAV3 knockdown abolishes the pro-osteogenic effect of ANKRD1 overexpression.","method":"Lentiviral ANKRD1 overexpression and knockdown in BMSCs, ALP activity, osteogenic gene qPCR, Wnt/β-catenin pathway analysis, CAV3 ubiquitination assay, epistasis (CAV3 knockdown rescue)","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay identifies mechanism; epistasis via CAV3 KD validates pathway position; single lab","pmids":["36958710"],"is_preprint":false}],"current_model":"ANKRD1/CARP is a stress-inducible, dual-compartment protein that resides in the sarcomeric I-band (bound to titin N2A domain, myopalladin, and calsequestrin-2) and translocates to the nucleus where it acts as a transcriptional co-repressor (of ANF, MMP13, androgen receptor targets) or co-activator (of p53), interacts with ERK1/2 and GATA4 to relay hypertrophic signals, inhibits NF-κB through direct binding to p50, and is rapidly degraded by the 26S proteasome via a PEST-motif-dependent mechanism; its mRNA stability is post-transcriptionally regulated by the RNA-binding protein RBMS1 during senescence, its nuclear import is controlled by a nuclear localization signal, and in non-muscle contexts it drives cancer-associated fibroblast activation by co-operating with AP-1 transcription factors, promotes ferroptosis by facilitating TRIM25-mediated K63-ubiquitination and degradation of ACSL3, and regulates cell motility through lamellipodia formation involving talin-1 and the integrin/FAK pathway."},"narrative":{"mechanistic_narrative":"ANKRD1/CARP is a stress-inducible, dual-compartment protein that couples the mechanical state of the sarcomere to gene expression, with broader roles in tissue injury, fibroblast activation, and cell motility [PMID:19608031, PMID:25770146]. In striated muscle it resides at the sarcomeric I-band through direct binding to the titin N2A domain and myopalladin, and to cardiac calsequestrin-2, with disease-associated mutations altering these interactions and CARP localization [PMID:19608031, PMID:15698842]. ANKRD1 translocates to the nucleus where it acts as a context-dependent transcriptional coregulator: it represses ANF, MMP13/MMP10 (via the AP-1 site, opposing c-Jun binding), and androgen-receptor target genes, while co-activating p53 to induce TP53, BAX and CDKN1A and destabilize MDM2 [PMID:24515436, PMID:23811403, PMID:29179447]. It relays hypertrophic signaling as part of an ANKRD1/ERK1/2/GATA4 complex that translocates to the nucleus upon adrenergic stimulation, with Ankrd1 required for phenylephrine-induced but not pressure-overload hypertrophy, and it feeds back on inflammatory signaling by binding the NF-κB p50 subunit to inhibit TNFα-induced transcription [PMID:25770146, PMID:26102030]. ANKRD1 abundance is tightly controlled by 26S proteasome-mediated degradation through a PEST motif and additional degrons, while its mRNA is stabilized by the RNA-binding protein RBMS1 during senescence [PMID:19589340, PMID:22892129, PMID:38769646]. Beyond muscle, ANKRD1 drives cancer-associated fibroblast activation under androgen-receptor negative control by promoting c-JUN/FOS (AP-1) association at effector gene loci, regulates cell spreading, migration and lamellipodia formation through talin-1 and the integrin/FAK pathway, and promotes ferroptosis by facilitating TRIM25-mediated K63-ubiquitination and degradation of ACSL3 [PMID:38310103, PMID:25452119, PMID:40362467, PMID:39285846]. Compartment-specific studies indicate nuclear ANKRD1 exacerbates pathological cardiac remodeling whereas cytosolic ANKRD1 is cardioprotective, and blocking its nuclear import improves cardiac function [PMID:38475992].","teleology":[{"year":2005,"claim":"Established that ANKRD1 has a direct structural partner in the cardiac calcium-handling apparatus, anchoring it in the heart beyond a purely nuclear role.","evidence":"Pull-down, blot-overlay, Co-IP and peptide mapping from heart extracts with immunohistochemistry","pmids":["15698842"],"confidence":"High","gaps":["Functional consequence of the ANKRD1–CASQ2 interaction for calcium handling not defined","Whether binding is dynamic or constitutive unresolved"]},{"year":2008,"claim":"Linked ANKRD1 protein stability to its transcriptional repressor function, showing a disease mutation that stabilizes the protein and enhances repression of the ANF promoter.","evidence":"In vitro calpain degradation assay and reporter gene assay in HeLa cells with a TAPVR-associated mutation","pmids":["18273862"],"confidence":"Medium","gaps":["Mechanism connecting stability to repression not resolved","Calpain role in vivo not tested"]},{"year":2009,"claim":"Defined ANKRD1 as a node in sarcomeric stretch sensing by mapping cardiomyopathy mutations onto titin/myopalladin and talin-1/FHL2 interactions and onto altered stretch-induced and repressor activity.","evidence":"Co-IP and localization in neonatal rat cardiomyocytes, yeast two-hybrid, stretch and reporter/hypertrophy assays with HCM and DCM mutants","pmids":["19608031","19608030","19525294"],"confidence":"High","gaps":["Direct demonstration that mutant binding changes cause disease in vivo lacking at this stage","Whether stretch directly modulates ANKRD1 conformation untested"]},{"year":2009,"claim":"Identified the proteasome and a PEST motif as the principal control of ANKRD1 turnover, framing it as a rapidly degraded stress-inducible factor.","evidence":"Proteasome inhibitor treatment, PEST motif mutagenesis, and pulse-chase analysis","pmids":["19589340"],"confidence":"Medium","gaps":["Responsible E3 ligase not identified","Other contributing degrons uncharacterized"]},{"year":2010,"claim":"Placed ANKRD1 in a reciprocal regulatory loop with p53, acting as a co-activator while being a p53 transcriptional target.","evidence":"Protein array, in vivo/in vitro Co-IP, and promoter reporter assay","pmids":["20599664"],"confidence":"Medium","gaps":["Mechanism of p53 co-activation undefined","Physiological context of the loop not established"]},{"year":2012,"claim":"Demonstrated co-dependence of ANKRD1 and GATA4 for myofilament gene expression and sarcomere integrity, with GATA4 driving the ANKRD1 promoter.","evidence":"Reporter assay, siRNA knockdown, adenoviral overexpression and doxorubicin rescue in cardiomyocytes","pmids":["22532871"],"confidence":"Medium","gaps":["Direct ANKRD1 occupancy of myofilament gene promoters not shown","Single-lab in vitro evidence"]},{"year":2012,"claim":"Showed cell-type-specific control of ANKRD1 half-life by the proteasome, explaining short-lived versus stable pools across cardiomyocytes and endothelium.","evidence":"Proteasome inhibition and pulse-chase half-life measurement in rat ventricular myocytes and endothelial cells","pmids":["22892129"],"confidence":"Medium","gaps":["Molecular basis for cell-type differences in half-life unknown","Density-dependent degradation mechanism unresolved"]},{"year":2013,"claim":"Resolved that distinct HCM mutations act through different mechanisms—gain-of-function versus proteasome-driven instability and dominant-negative effects—directly tying degradation to contractile phenotype.","evidence":"AAV gene transfer into engineered heart tissue with contractile analysis and proteasome inhibition","pmids":["23572067"],"confidence":"Medium","gaps":["Patient-level causality not established","How instability translates to relaxation defects mechanistically unclear"]},{"year":2013,"claim":"Extended ANKRD1's repressor role to androgen-receptor signaling in muscle, with testosterone downregulating Ankrd1 and ANKRD1 repressing AR target genes.","evidence":"Co-IP and ARE/MAFbx reporter assays with testosterone-regulated gene qPCR in myoblasts","pmids":["23811403"],"confidence":"Medium","gaps":["Whether ANKRD1 binds AR target promoters directly not shown","In vivo relevance untested"]},{"year":2014,"claim":"Defined a transcriptional repression mechanism in which ANKRD1 antagonizes c-Jun at AP-1 sites to silence matrix metalloproteinases, validated in knockout fibroblasts.","evidence":"Yeast two-hybrid, Co-IP, EMSA, ChIP, promoter assays and Ankrd1-null mouse analysis","pmids":["24515436"],"confidence":"High","gaps":["Role of the nucleolin interaction unclear","Direct DNA binding versus AP-1 sequestration not fully separated"]},{"year":2014,"claim":"Established ANKRD1 as required for fibroblast spreading, migration, collagen contraction and wound healing, demonstrating a non-muscle structural/motility function in vivo.","evidence":"Global Ankrd1 KO mouse with migration, 3D gel contraction, adenoviral rescue, and wound/ischemic flap models","pmids":["25452119"],"confidence":"High","gaps":["Molecular effector linking ANKRD1 to actin organization not pinpointed here","Cell-autonomous versus systemic contribution not dissected"]},{"year":2015,"claim":"Identified the ANKRD1/ERK1/2/GATA4 signaling complex as the relay for adrenergic hypertrophy, with stimulus-specific requirement for Ankrd1.","evidence":"Co-IP, siRNA knockdown, adrenergic stimulation, and Ankrd1 KO mice with PE infusion versus TAC","pmids":["25770146"],"confidence":"High","gaps":["How ANKRD1 selectively couples to PE but not pressure-overload signaling unknown","Direct contacts within the complex not mapped"]},{"year":2015,"claim":"Showed ANKRD1 provides feedback inhibition of inflammatory signaling by binding NF-κB p50 and occupying an NF-κB site in the ANKRD2 promoter.","evidence":"Co-IP, siRNA, NF-κB reporter and ChIP in C2C12 myoblasts","pmids":["26102030"],"confidence":"Medium","gaps":["Structural basis of p50 binding undefined","In vivo significance of the feedback loop untested"]},{"year":2015,"claim":"Connected ANKRD1 to catecholamine biosynthesis, with ERK5 inducing it and ANKRD1 stabilizing tyrosine hydroxylase by reducing its ubiquitination.","evidence":"Microarray with ERK5/ERK1/2 inhibitors, siRNA, ubiquitination and catecholamine assays in PC12 cells","pmids":["26739108"],"confidence":"Medium","gaps":["Mechanism by which ANKRD1 reduces TH ubiquitination unknown","Relevance to neuronal physiology in vivo untested"]},{"year":2017,"claim":"Positioned ANKRD1 in the Hippo-RASSF1A axis as a YAP1 target that suppresses cancer cell growth in a p53-dependent manner.","evidence":"Reporter/expression assays, Co-IP, and colony formation in cancer cells","pmids":["29179447"],"confidence":"Medium","gaps":["Direct ANKRD1 regulation of MDM2 stability not mechanistically defined","Tumor-context specificity unclear"]},{"year":2019,"claim":"Showed gain of ANKRD1 in myocardium causes developmental and diastolic cardiac defects, reinforcing dose- and compartment-sensitive function and dynamic nucleo-sarcomeric localization.","evidence":"Myocardium-specific transgenic mice with histology, hemodynamics, myofibrillar assays and transcriptional profiling","pmids":["31688894"],"confidence":"High","gaps":["Trigger for nuclear versus sarcomeric partitioning not defined","Link between titin gene changes and dysfunction not mechanistically closed"]},{"year":2023,"claim":"Began to link ANKRD1 to ferroptosis through p53/SLC7A11/GPX4 in renal tubular cells.","evidence":"Lentiviral silencing/overexpression with Western blot of ferroptosis markers and Fe2+ assay in HK-2 cells","pmids":["36907445"],"confidence":"Low","gaps":["No direct epistasis experiment—pathway position inferred from marker changes only","Single-lab Western-blot readout","Direct ANKRD1 target in this axis not identified"]},{"year":2023,"claim":"Implicated ANKRD1 in osteogenic differentiation via CAV3 deubiquitination and Wnt/β-catenin activation.","evidence":"Lentiviral manipulation in BMSCs with ubiquitination assay and CAV3-knockdown epistasis","pmids":["36958710"],"confidence":"Medium","gaps":["How ANKRD1 reduces CAV3 ubiquitination unknown","In vivo bone phenotype untested"]},{"year":2024,"claim":"Defined ANKRD1 as an AR-repressed mesenchymal coregulator driving cancer-associated fibroblast activation through AP-1 (c-JUN/FOS) cooperation.","evidence":"ChIP, AP-1 Co-IP, knockdown, AR manipulation and orthotopic skin cancer model","pmids":["38310103"],"confidence":"High","gaps":["Whether ANKRD1 directly contacts AP-1 components mapped only by Co-IP","Generalizability beyond skin tumor context unestablished"]},{"year":2024,"claim":"Showed ANKRD1 promotes ferroptosis by enabling TRIM25-mediated K63-ubiquitination and degradation of ACSL3 in renal ischemia-reperfusion.","evidence":"IP-MS interactome, Co-IP, proximity ligation, ubiquitination assay and rAAV9 knockdown in vivo","pmids":["39285846"],"confidence":"High","gaps":["How ANKRD1 facilitates TRIM25 activity mechanistically unclear","Relationship to the p53/SLC7A11 ferroptosis route not reconciled"]},{"year":2024,"claim":"Demonstrated opposing roles of nuclear versus cytosolic ANKRD1 in heart failure and identified AGO2-driven transcription and NLS-blocking peptides as therapeutic levers.","evidence":"Compartment-specific AAV9 overexpression, TAC model, reporter assays and pharmacological intervention (ivermectin, ANPep)","pmids":["38475992"],"confidence":"Medium","gaps":["Molecular signal partitioning ANKRD1 between compartments not defined","Durability/safety of import blockade untested"]},{"year":2024,"claim":"Connected ANKRD1 to integrin/FAK-based motility and myoblast fate via transcriptional repression of integrin genes and lamellipodial talin-1 colocalization.","evidence":"siRNA/overexpression, RNA-seq, Itga6 reporter, FAK phosphorylation, and immunofluorescence co-localization in myoblasts and renal carcinoma cells","pmids":["38988048","40362467"],"confidence":"Medium","gaps":["Whether nuclear repression and lamellipodial localization are the same pool unclear","Direct ANKRD1–talin-1 binding not biochemically resolved"]},{"year":2024,"claim":"Showed ANKRD1 regulates cardiomyocyte cell cycle and regeneration through cyclin D1.","evidence":"Cardiomyocyte-specific knockdown/overexpression in neonatal apical resection and adult MI models with cyclin D1 analysis","pmids":["39299480"],"confidence":"Medium","gaps":["Direct link between ANKRD1 and cyclin D1 regulation not mechanistically defined","Translatability to human cardiac repair untested"]},{"year":2024,"claim":"Identified post-transcriptional control of ANKRD1 by RBMS1-mediated mRNA stabilization during senescence.","evidence":"ASO pulldown-MS, RIP, mRNA half-life, RBMS1 manipulation and heterologous reporter","pmids":["38769646"],"confidence":"Medium","gaps":["Functional output of senescence-associated ANKRD1 induction not defined","RBMS1 binding site fine-mapping incomplete"]},{"year":null,"claim":"It remains unknown what molecular switch governs ANKRD1 partitioning between its sarcomeric/cytosolic structural role and its nuclear transcriptional role, and which E3 ligase enforces its PEST-dependent turnover.","evidence":"No timeline discovery defines the compartment-switch signal or the responsible degradation machinery","pmids":[],"confidence":"Low","gaps":["Compartment-partitioning signal unidentified","E3 ligase for ANKRD1 degradation unknown","Unifying logic across muscle, fibroblast, cancer and ferroptosis roles unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,10,12,20,21]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,8,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,16,19]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[10,20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,10,17,18]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,8,17,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18,23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,12,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[19]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,25,19]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[0,7,17]}],"complexes":["ANKRD1/ERK1/2/GATA4 sarcomeric signaling complex"],"partners":["TTN","MYPN","CASQ2","TLN1","GATA4","TP53","NFKB1","TRIM25"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15327","full_name":"Ankyrin repeat domain-containing protein 1","aliases":["Cardiac ankyrin repeat protein","Cytokine-inducible gene C-193 protein","Cytokine-inducible nuclear protein"],"length_aa":319,"mass_kda":36.3,"function":"May play an important role in endothelial cell activation. May act as a nuclear transcription factor that negatively regulates the expression of cardiac genes. Induction seems to be correlated with apoptotic cell death in hepatoma cells","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q15327/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ANKRD1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ANKRD1","total_profiled":1310},"omim":[{"mim_id":"615248","title":"CARDIOMYOPATHY, DILATED, 1KK; CMD1KK","url":"https://www.omim.org/entry/615248"},{"mim_id":"610734","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 2; ANKRD2","url":"https://www.omim.org/entry/610734"},{"mim_id":"609599","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 1; ANKRD1","url":"https://www.omim.org/entry/609599"},{"mim_id":"608517","title":"MYOPALLADIN; MYPN","url":"https://www.omim.org/entry/608517"},{"mim_id":"602267","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 8; ADAM8","url":"https://www.omim.org/entry/602267"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli fibrillar center","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":6125.5}],"url":"https://www.proteinatlas.org/search/ANKRD1"},"hgnc":{"alias_symbol":["C-193","ALRP","CARP","CVARP","MCARP"],"prev_symbol":[]},"alphafold":{"accession":"Q15327","domains":[{"cath_id":"1.25.40.20","chopping":"120-244","consensus_level":"high","plddt":97.2492,"start":120,"end":244}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15327","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15327-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15327-F1-predicted_aligned_error_v6.png","plddt_mean":82.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ANKRD1","jax_strain_url":"https://www.jax.org/strain/search?query=ANKRD1"},"sequence":{"accession":"Q15327","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15327.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15327/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15327"}},"corpus_meta":[{"pmid":"19608031","id":"PMC_19608031","title":"Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy.","date":"2009","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19608031","citation_count":123,"is_preprint":false},{"pmid":"19608030","id":"PMC_19608030","title":"ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene.","date":"2009","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19608030","citation_count":115,"is_preprint":false},{"pmid":"30814490","id":"PMC_30814490","title":"RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30814490","citation_count":95,"is_preprint":false},{"pmid":"11313344","id":"PMC_11313344","title":"Yeast ERV2p is the first microsomal FAD-linked sulfhydryl oxidase of the Erv1p/Alrp protein family.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11313344","citation_count":87,"is_preprint":false},{"pmid":"25770146","id":"PMC_25770146","title":"Targeted inhibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abrogates phenylephrine-induced cardiomyocyte hypertrophy.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25770146","citation_count":66,"is_preprint":false},{"pmid":"19525294","id":"PMC_19525294","title":"Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy.","date":"2009","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/19525294","citation_count":65,"is_preprint":false},{"pmid":"20599664","id":"PMC_20599664","title":"A novel role for cardiac ankyrin repeat protein Ankrd1/CARP as a co-activator of the p53 tumor suppressor protein.","date":"2010","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/20599664","citation_count":62,"is_preprint":false},{"pmid":"24531715","id":"PMC_24531715","title":"Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24531715","citation_count":52,"is_preprint":false},{"pmid":"22532871","id":"PMC_22532871","title":"Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22532871","citation_count":49,"is_preprint":false},{"pmid":"18273862","id":"PMC_18273862","title":"Transcriptional deregulation and a missense mutation define ANKRD1 as a candidate gene for total anomalous pulmonary venous return.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18273862","citation_count":47,"is_preprint":false},{"pmid":"29179447","id":"PMC_29179447","title":"The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29179447","citation_count":44,"is_preprint":false},{"pmid":"25452119","id":"PMC_25452119","title":"Global deletion of Ankrd1 results in a wound-healing phenotype associated with dermal fibroblast dysfunction.","date":"2014","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25452119","citation_count":43,"is_preprint":false},{"pmid":"18980987","id":"PMC_18980987","title":"Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18980987","citation_count":40,"is_preprint":false},{"pmid":"23572067","id":"PMC_23572067","title":"Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.","date":"2013","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23572067","citation_count":40,"is_preprint":false},{"pmid":"26102030","id":"PMC_26102030","title":"ANKRD1 modulates inflammatory responses in C2C12 myoblasts through feedback inhibition of NF-κB signaling activity.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26102030","citation_count":39,"is_preprint":false},{"pmid":"19597856","id":"PMC_19597856","title":"Porcine muscle sensory attributes associate with major changes in gene networks involving CAPZB, ANKRD1, and CTBP2.","date":"2009","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19597856","citation_count":39,"is_preprint":false},{"pmid":"24515436","id":"PMC_24515436","title":"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24515436","citation_count":37,"is_preprint":false},{"pmid":"25961010","id":"PMC_25961010","title":"Induction of Ankrd1 in Dilated Cardiomyopathy Correlates with the Heart Failure Progression.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25961010","citation_count":34,"is_preprint":false},{"pmid":"12089204","id":"PMC_12089204","title":"Accumulation of the mitochondrial form of the sulphydryl oxidase Erv1p/Alrp during the early stages of spermatogenesis.","date":"2002","source":"The Journal of experimental biology","url":"https://pubmed.ncbi.nlm.nih.gov/12089204","citation_count":33,"is_preprint":false},{"pmid":"31688894","id":"PMC_31688894","title":"Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction.","date":"2020","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/31688894","citation_count":31,"is_preprint":false},{"pmid":"38310103","id":"PMC_38310103","title":"ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38310103","citation_count":30,"is_preprint":false},{"pmid":"15698842","id":"PMC_15698842","title":"ANKRD1 specifically binds CASQ2 in heart extracts and both proteins are co-enriched in piglet cardiac Purkinje cells.","date":"2005","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15698842","citation_count":30,"is_preprint":false},{"pmid":"21291353","id":"PMC_21291353","title":"Alrp, a survival factor that controls the apoptotic process of regenerating liver after partial hepatectomy in rats.","date":"2011","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/21291353","citation_count":28,"is_preprint":false},{"pmid":"19589340","id":"PMC_19589340","title":"Intracellular ANKRD1 protein levels are regulated by 26S proteasome-mediated degradation.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19589340","citation_count":25,"is_preprint":false},{"pmid":"22085644","id":"PMC_22085644","title":"Loss of desmin triggers mechanosensitivity and up-regulation of Ankrd1 expression through Akt-NF-κB signaling pathway in smooth muscle cells.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22085644","citation_count":25,"is_preprint":false},{"pmid":"36907445","id":"PMC_36907445","title":"Ferroptosis in calcium oxalate kidney stone formation and the possible regulatory mechanism of ANKRD1.","date":"2023","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36907445","citation_count":23,"is_preprint":false},{"pmid":"34157504","id":"PMC_34157504","title":"Baoyuan decoction (BYD) attenuates cardiac hypertrophy through ANKRD1-ERK/GATA4 pathway in heart failure after acute myocardial infarction.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34157504","citation_count":21,"is_preprint":false},{"pmid":"19341785","id":"PMC_19341785","title":"Intron retention generates ANKRD1 splice variants that are co-regulated with the main transcript in normal and failing myocardium.","date":"2009","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/19341785","citation_count":19,"is_preprint":false},{"pmid":"36958710","id":"PMC_36958710","title":"ANKRD1 activates the Wnt signaling pathway by modulating CAV3 expression and thus promotes BMSC osteogenic differentiation and bone formation in ovariectomized mice.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/36958710","citation_count":18,"is_preprint":false},{"pmid":"26739108","id":"PMC_26739108","title":"ERK5 induces ankrd1 for catecholamine biosynthesis and homeostasis in adrenal medullary cells.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26739108","citation_count":17,"is_preprint":false},{"pmid":"38475992","id":"PMC_38475992","title":"Nuclear AGO2 promotes myocardial remodeling by activating ANKRD1 transcription in failing hearts.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38475992","citation_count":15,"is_preprint":false},{"pmid":"23811403","id":"PMC_23811403","title":"Ankrd1 is a transcriptional repressor for the androgen receptor that is downregulated by testosterone.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23811403","citation_count":15,"is_preprint":false},{"pmid":"36361958","id":"PMC_36361958","title":"Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R-Ankrd1-P53 Signaling Pathway.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36361958","citation_count":15,"is_preprint":false},{"pmid":"39285846","id":"PMC_39285846","title":"ANKRD1 aggravates renal ischaemia‒reperfusion injury via promoting TRIM25-mediated ubiquitination of ACSL3.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39285846","citation_count":13,"is_preprint":false},{"pmid":"22892129","id":"PMC_22892129","title":"26S proteasome regulation of Ankrd1/CARP in adult rat ventricular myocytes and human microvascular endothelial cells.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22892129","citation_count":12,"is_preprint":false},{"pmid":"38988048","id":"PMC_38988048","title":"Ankrd1 inhibits the FAK/Rho-GTPase/F-actin pathway by downregulating ITGA6 transcriptional to regulate myoblast functions.","date":"2024","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38988048","citation_count":9,"is_preprint":false},{"pmid":"34583851","id":"PMC_34583851","title":"LncRNA RGMB-AS1 up-regulates ANKRD1 Through Competitively Sponging miR-3614-5p to Promote OSA Cell Proliferation and Invasion.","date":"2021","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/34583851","citation_count":9,"is_preprint":false},{"pmid":"38769646","id":"PMC_38769646","title":"Increased ANKRD1 Levels in Early Senescence Mediated by RBMS1-Elicited ANKRD1 mRNA Stabilization.","date":"2024","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38769646","citation_count":7,"is_preprint":false},{"pmid":"39409926","id":"PMC_39409926","title":"ANKRD1 Promotes Breast Cancer Metastasis by Activating NF-κB-MAGE-A6 Pathway.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39409926","citation_count":6,"is_preprint":false},{"pmid":"38683293","id":"PMC_38683293","title":"ANKRD1 expression is aberrantly upregulated in the mdm mouse model of muscular dystrophy and induced by stretch through NFκB.","date":"2024","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/38683293","citation_count":5,"is_preprint":false},{"pmid":"38575872","id":"PMC_38575872","title":"Integrating miRNA and full-length transcriptome profiling to elucidate the mechanism of muscle growth in Muscovy ducks reveals key roles for miR-301a-3p/ANKRD1.","date":"2024","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38575872","citation_count":4,"is_preprint":false},{"pmid":"39920300","id":"PMC_39920300","title":"Ankrd1 as a potential biomarker for the transition from acute kidney injury to chronic kidney disease.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39920300","citation_count":3,"is_preprint":false},{"pmid":"36551326","id":"PMC_36551326","title":"Genetic Ablation of Ankrd1 Mitigates Cardiac Damage during Experimental Autoimmune Myocarditis in Mice.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36551326","citation_count":3,"is_preprint":false},{"pmid":"39299480","id":"PMC_39299480","title":"Ankrd1 regulates endogenous cardiac regeneration in mice by modulating cyclin D1.","date":"2024","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39299480","citation_count":2,"is_preprint":false},{"pmid":"40362467","id":"PMC_40362467","title":"Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40362467","citation_count":2,"is_preprint":false},{"pmid":"34212557","id":"PMC_34212557","title":"Clinical and pathohistological characteristics of Alport spectrum disorder caused by COL4A4 mutation c.193-2A>C: a case series.","date":"2021","source":"Croatian medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34212557","citation_count":2,"is_preprint":false},{"pmid":"26291968","id":"PMC_26291968","title":"Hb G-Waimanalo [A1] [α64(E13)Asp→Asn; HBA1: c.193 G > A] with Decreased Oxygen Affinity.","date":"2015","source":"Hemoglobin","url":"https://pubmed.ncbi.nlm.nih.gov/26291968","citation_count":1,"is_preprint":false},{"pmid":"40516143","id":"PMC_40516143","title":"DNA-methylation-mediated silencing of lncRNA PP7080 promotes the progression of gastric cancer by regulating ANKRD1 expression.","date":"2025","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40516143","citation_count":0,"is_preprint":false},{"pmid":"38396247","id":"PMC_38396247","title":"Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation.","date":"2024","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38396247","citation_count":0,"is_preprint":false},{"pmid":"41770518","id":"PMC_41770518","title":"ANKRD1 expression and functional mechanism in stomach adenocarcinoma.","date":"2026","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/41770518","citation_count":0,"is_preprint":false},{"pmid":"41865688","id":"PMC_41865688","title":"Yifei Sanjie pill combined with gefitinib reduces the progression of EGFR-TKIs-resistant non-small cell lung cancer via YAP/ANKRD1 axis.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41865688","citation_count":0,"is_preprint":false},{"pmid":"41764190","id":"PMC_41764190","title":"ANKRD1 sustains a neurogenic BMSC niche and counters cognitive aging.","date":"2026","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/41764190","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.29.685384","title":"The Age-Dependent Resident Myonuclear Multi-Omic Response to a Skeletal Muscle Hypertrophic Stimulus","date":"2025-10-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.29.685384","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.05.652263","title":"S4, a Selective Androgen Receptor Modulator, Suppresses Breast Cancer Progression via Cell Cycle Arrest, Apoptosis, and Metabolic Alterations","date":"2025-05-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.05.652263","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.15.648883","title":"Muscle spatial transcriptomic reveals heterogeneous profiles in untreated juvenile dermatomyositis and the persistence of pathological signature after remission","date":"2025-04-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.15.648883","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.02.626422","title":"Aldh3a1-mediated detoxification of reactive aldehydes contributes to distinct muscle responses to Amyotrophic Lateral Sclerosis progression","date":"2024-12-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.626422","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.27.609955","title":"Bronchopulmonary Dysplasia with Pulmonary Hypertension Associates with Loss of Semaphorin Signaling and Functional Decrease in FOXF1 Expression","date":"2024-08-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.27.609955","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.02.24310874","title":"Genetics of Cardiac Aging Implicate Organ-Specific Variation","date":"2024-08-06","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.02.24310874","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33116,"output_tokens":7206,"usd":0.103719,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16523,"output_tokens":6892,"usd":0.127458,"stage2_stop_reason":"end_turn"},"total_usd":0.231177,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"ANKRD1/CARP physically interacts with the N2A domain of titin/connectin and with myopalladin in cardiomyocytes; HCM-associated missense mutations (Pro52Ala, Thr123Met, Ile280Val) increase binding of CARP to both titin/connectin and myopalladin, and cause abnormal localization of CARP in neonatal rat cardiomyocytes.\",\n      \"method\": \"Co-immunoprecipitation, cellular localization in neonatal rat cardiomyocytes with myc-tagged mutant CARP\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with functional follow-up (localization assay), single lab but two orthogonal methods\",\n      \"pmids\": [\"19608031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DCM-associated ANKRD1 mutations (M184I and P105S) abolish or reduce binding of CARP to Talin-1, and M184I also disrupts binding to FHL2, as measured by yeast two-hybrid; these mutations alter stretch-mediated gene expression without changing intracellular localization of mutant CARP proteins.\",\n      \"method\": \"Yeast two-hybrid, quantitative real-time RT-PCR of stretch-induced gene expression in myoblastoid cell lines\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional stretch assay, single lab\",\n      \"pmids\": [\"19608030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DCM-associated ANKRD1 mutant proteins (sequenced from 231 DCM patients) show significantly reduced transcriptional repressor activity in reporter gene assays and greater phenylephrine-induced hypertrophy when expressed in neonatal rat cardiomyocytes, indicating loss-of-function for transcriptional repression.\",\n      \"method\": \"Reporter gene assay (transfection in neonatal rat cardiomyocytes), hypertrophy assay\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter gene assay plus hypertrophy phenotype, single lab, two orthogonal readouts\",\n      \"pmids\": [\"19525294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A TAPVR-associated missense mutation in ANKRD1 enhances protein stability (resistance to calpain-mediated degradation) and increases its transcriptional repression activity on the ANF promoter.\",\n      \"method\": \"In vitro calpain-mediated degradation assay, reporter gene analysis in transfected HeLa cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro degradation assay combined with reporter gene assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"18273862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ANKRD1 protein levels are regulated by 26S proteasome-mediated degradation; a PEST motif within ANKRD1 is critical for this degradation, though other degrons also contribute.\",\n      \"method\": \"Proteasome inhibitor treatment, PEST motif mutagenesis, pulse-chase analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct mutagenesis of degradation motif with proteasome inhibitor validation, single lab\",\n      \"pmids\": [\"19589340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ANKRD1/CARP physically interacts with the tumor suppressor p53 both in vivo and in vitro, and functions as a transcriptional co-activator that moderately upregulates p53 activity; p53 in turn acts as an upstream effector that upregulates the proximal ANKRD1 promoter.\",\n      \"method\": \"Protein array, co-immunoprecipitation (in vivo and in vitro), reporter gene assay (promoter activity)\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein array identification confirmed by Co-IP and reporter assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20599664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ANKRD1 is part of a sarcomeric signaling complex with ERK1/2 and GATA4 in neonatal rat ventricular myocytes; phenylephrine treatment induces ERK1/2 and GATA4 phosphorylation and nuclear translocation of the ANKRD1/ERK/GATA4 complex. Knockdown of Ankrd1 attenuates ERK1/2 and GATA4 phosphorylation and prevents PE-induced cardiomyocyte growth. Ankrd1 null mice fail to develop PE-induced cardiac hypertrophy but develop normal hypertrophy in response to pressure overload (TAC).\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, adrenergic agonist stimulation assays, Ankrd1 knockout mouse with PE infusion and TAC\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro siRNA knockdown with phosphorylation readout, in vivo KO mouse with two distinct hypertrophic stimuli, multiple orthogonal methods across in vitro and in vivo models\",\n      \"pmids\": [\"25770146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GATA4 acts upstream of ANKRD1 by activating the proximal CARP/ANKRD1 promoter; CARP/ANKRD1 knockdown inhibits myofilament gene transcription and induces sarcomere disarray; CARP depletion abolishes GATA4 overexpression-mediated rescue of doxorubicin-induced sarcomere disorganization, demonstrating co-dependent roles for GATA4 and CARP in sarcomere gene expression and structural maintenance.\",\n      \"method\": \"Co-transfection reporter assay, siRNA knockdown, adenoviral overexpression, doxorubicin treatment in cardiomyocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay for promoter activation, siRNA knockdown with defined sarcomere phenotype, epistasis via rescue experiment, single lab\",\n      \"pmids\": [\"22532871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ANKRD1 selectively binds cardiac calsequestrin-2 (CASQ2) in heart extracts, confirmed by pull-down, blot-overlay, and co-immunoprecipitation; five non-overlapping binding sequences for CASQ2 were mapped on ANKRD1, and three ANKRD1-binding peptides were identified on CASQ2; endogenous ANKRD1 and CASQ2 are co-enriched in cardiac Purkinje cells.\",\n      \"method\": \"Pull-down from heart tissue extracts, blot-overlay assay, co-immunoprecipitation, peptide mapping, immunohistochemistry\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three orthogonal binding assays (pull-down, blot-overlay, Co-IP) plus peptide epitope mapping, single lab\",\n      \"pmids\": [\"15698842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ANKRD1 binds the p50 subunit of NF-κB (confirmed by co-immunoprecipitation) and inhibits TNFα-induced NF-κB transcriptional activity in C2C12 myoblasts; ANKRD1 also binds chromatin at an NF-κB binding site in the ANKRD2 promoter in a NF-κB-dependent manner, providing feedback inhibition of NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, NF-κB reporter assay, ChIP assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus functional reporter assay, single lab, multiple methods\",\n      \"pmids\": [\"26102030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site; ANKRD1 associates with nucleolin (by yeast two-hybrid and co-immunoprecipitation); deletion of Ankrd1 elevates MMP13 mRNA and protein; ChIP shows greater c-Jun binding to the MMP13 AP-1 site in Ankrd1-null fibroblasts; ANKRD1 also represses MMP10.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, EMSA, ChIP, promoter activity assay, qPCR, protein analysis in Ankrd1-/- mice\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid, Co-IP, EMSA, ChIP, and KO mouse validation all converge on same mechanism, single lab but five orthogonal methods\",\n      \"pmids\": [\"24515436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Global deletion of Ankrd1 impairs dermal fibroblast spreading and migration on collagen and fibronectin, abolishes contraction of 3D collagen gels, and delays wound closure in vivo; adenoviral re-expression of ANKRD1 restores collagen gel contraction, actin fiber organization, and rescues ischemic skin flap necrosis.\",\n      \"method\": \"Global Ankrd1 KO mouse (Sox2-cre), fibroblast migration and spreading assays, 3D collagen gel contraction, adenoviral reconstitution, excisional wound and ischemic flap models\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotypes validated by adenoviral rescue both in vitro and in vivo\",\n      \"pmids\": [\"25452119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ANKRD1 binds the androgen receptor (AR) (by co-immunoprecipitation) and acts as a transcriptional repressor of AR-mediated gene expression; testosterone reduces Ankrd1 mRNA ~50% in L6.AR myoblasts; Ankrd1 overexpression blocks testosterone-induced reporter gene activity and modulates expression of MEF2d, myogenin, p21, and TnnI1 downstream of AR.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay (ARE-Luc, MAFbx-Luc), qPCR of testosterone-regulated genes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirmed physical interaction, reporter assay confirms functional repression, single lab\",\n      \"pmids\": [\"23811403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HCM-associated ANKRD1 mutations have distinct functional consequences in engineered heart tissues: T123M produces a gain-of-function with higher contractile force and velocities and correct sarcomere incorporation; P52A and I280V are highly unstable, excluded from the sarcomere, and rapidly degraded by the proteasome; proteasome inhibition stabilizes P52A and I280V, enabling sarcomere incorporation, and I280V then produces prolonged relaxation (dominant-negative effect).\",\n      \"method\": \"Adeno-associated virus gene transfer into engineered heart tissues, contractile parameter analysis, proteasome inhibitor (epoxomicin) treatment\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay in engineered tissue with pharmacological manipulation, single lab\",\n      \"pmids\": [\"23572067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ANKRD1 interacts with desmin in smooth muscle cells; siRNA knockdown of desmin upregulates Ankrd1 expression via activation of the Akt/IKKα/IκBα/NF-κB signaling cascade; NF-κB directly binds the Ankrd1 promoter to drive its transcription as shown by luciferase reporter assay.\",\n      \"method\": \"siRNA knockdown, Western blot for pathway phosphorylation, pharmacological inhibitors of Akt/IKK/NF-κB, siRNA against p50/p65, luciferase reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic epistasis combined with reporter assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22085644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ANKRD1 is a YAP1 target gene induced by RASSF1A co-expression; ANKRD1 physically interacts with p53, induces TP53, BAX, and CDKN1A expression, destabilizes MDM2, and reduces cancer cell colony formation in a p53-dependent manner.\",\n      \"method\": \"Reporter/expression assays, co-immunoprecipitation (ANKRD1–p53 interaction), colony formation assay, gene expression analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirms protein interaction; functional epistasis with p53 shown by colony assay; single lab\",\n      \"pmids\": [\"29179447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK5, but not ERK1/2, induces Ankrd1 expression in PC12 adrenal cells; Ankrd1 stabilizes tyrosine hydroxylase (TH) protein (without changing TH mRNA), reduces TH ubiquitination, and is required for catecholamine biosynthesis during neural differentiation.\",\n      \"method\": \"Microarray with ERK5/ERK1/2-specific inhibitors, siRNA knockdown, ubiquitination assay, catecholamine biosynthesis measurement\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — microarray target identification confirmed by siRNA knockdown with ubiquitination and biochemical readouts, single lab\",\n      \"pmids\": [\"26739108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ANKRD1 overexpression in mouse myocardium causes sinus venosus defect during development through impaired remodeling; adult transgenic hearts develop progressive diastolic dysfunction with impaired lusitropism, sarcomere disassembly, and altered titin gene expression; embryonic overexpression transiently activates GATA4-Nkx2.5 transcription. ANKRD1 has dynamic nucleo-sarcomeric localization in developing cardiomyocytes.\",\n      \"method\": \"Transgenic mouse overexpression (myocardium-specific), histological analysis, hemodynamic measurements, myofibrillar functional assays, transcriptional profiling\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic mouse model with histological, hemodynamic, and molecular readouts across developmental and adult timepoints, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"31688894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Nuclear AGO2 activates ANKRD1 transcription in failing cardiomyocytes; nuclear ANKRD1 overexpression exacerbates cardiac remodeling by inducing MYH7 (pathological), while cytosolic ANKRD1 appears cardioprotective; ivermectin and an ANKRD1 nuclear localization signal mimetic peptide (ANPep) block ANKRD1 nuclear import and improve cardiac function in TAC-induced heart failure mice.\",\n      \"method\": \"Recombinant AAV9 overexpression (nuclear vs. cytosolic AGO2/ANKRD1), TAC mouse model, mechanistic reporter assays, pharmacological intervention with ivermectin and ANPep\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — compartment-specific AAV overexpression with functional in vivo cardiac readouts and pharmacological rescue, single lab\",\n      \"pmids\": [\"38475992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANKRD1 promotes ACSL3 degradation by facilitating TRIM25-mediated K63-linked ubiquitination of ACSL3, thereby amplifying lipid peroxidation and ferroptosis during renal ischemia-reperfusion injury; knockdown of ANKRD1 in mouse kidneys (rAAV9) reduces renal damage and ferroptosis.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry (interactome), Co-IP, proximity ligation assay, ubiquitination assay, rAAV9-mediated knockdown in vivo, cell viability and lipid peroxidation assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — IP-MS interactome followed by Co-IP, proximity ligation, and ubiquitination assay, validated in vivo with rAAV knockdown, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"39285846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANKRD1 is a mesenchymal-specific transcriptional coregulator under direct androgen receptor (AR) negative control; ANKRD1 drives cancer-associated fibroblast (CAF) activation by binding regulatory regions of myofibroblast CAF effector genes and promoting c-JUN and FOS (AP-1) association; targeting ANKRD1 disrupts AP-1 complex formation and reverses CAF activation in an orthotopic skin cancer model.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), Co-IP for AP-1 complex, siRNA/knockdown, AR overexpression/loss, orthotopic mouse tumor model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP confirms ANKRD1 binding to target gene regulatory regions, Co-IP shows AP-1 complex disruption, in vivo orthotopic model validates functional consequence, multiple orthogonal methods\",\n      \"pmids\": [\"38310103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANKRD1 knockdown in C2C12 myoblasts decreases proliferation but increases differentiation; mechanistically, Ankrd1 represses the Itga6 promoter (shown by dual-luciferase reporter assay), and its knockdown upregulates ITGA6, leading to enhanced FAK phosphorylation and activation of the FAK/Rho-GTPase/F-actin pathway.\",\n      \"method\": \"siRNA knockdown, overexpression, RNA-seq, dual-luciferase reporter assay for Itga6 promoter, FAK phosphorylation assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay confirms transcriptional regulation of Itga6, combined with RNA-seq and signaling pathway analysis, single lab\",\n      \"pmids\": [\"38988048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANKRD1 promotes lamellipodia formation and cell motility in clear cell renal cell carcinoma cells; ANKRD1 colocalizes with F-actin and talin-1 in lamellipodia upon phorbol ester stimulation; ANKRD1 depletion represses talin-1-mediated integrin pathway activation and reduces lamellipodia formation.\",\n      \"method\": \"siRNA knockdown, overexpression, immunofluorescence co-localization, migration assay, integrin pathway activation analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-localization by immunofluorescence plus knockdown migration phenotype, single lab\",\n      \"pmids\": [\"40362467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RBMS1 RNA-binding protein stabilizes ANKRD1 mRNA during early senescence; RBMS1 relocates from nucleus to cytoplasm after etoposide treatment, binds a region proximal to the ANKRD1 coding sequence, and silencing RBMS1 reduces while overexpressing RBMS1 enhances ANKRD1 mRNA half-life.\",\n      \"method\": \"Antisense oligomer pulldown with mass spectrometry, ribonucleoprotein immunoprecipitation, mRNA half-life measurement, RBMS1 siRNA and overexpression, heterologous reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ASO pulldown plus RIP confirms RBMS1 binding; functional mRNA stability shown by half-life assay and reporter, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38769646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Ankrd1 regulates cardiomyocyte cell cycle and cardiac regeneration, at least in part through cyclin D1; cardiomyocyte-specific Ankrd1 knockdown inhibits myocardial regeneration after apical resection in neonatal mice, and cardiomyocyte-specific overexpression promotes cardiac repair after adult myocardial infarction.\",\n      \"method\": \"Ankrd1 cardiomyocyte-specific knockdown and overexpression, neonatal apical resection model, adult MI model, cyclin D1 mechanistic analysis\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cardiomyocyte-specific genetic manipulation in two distinct injury models with cyclin D1 mechanistic link, single lab\",\n      \"pmids\": [\"39299480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The 26S proteasome is the dominant regulator of ANKRD1/CARP degradation in both adult rat ventricular myocytes and human microvascular endothelial cells; ANKRD1/CARP half-life is significantly longer in cardiomyocytes (hours) than in endothelial cells (minutes), and higher endothelial cell density decreases ANKRD1 protein without affecting mRNA.\",\n      \"method\": \"Proteasome inhibitor treatment, protein half-life measurement (pulse-chase), cell density manipulation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological proteasome inhibition combined with protein half-life analysis in two cell types, single lab\",\n      \"pmids\": [\"22892129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANKRD1 regulates ferroptosis in HK-2 renal tubular cells through the p53/SLC7A11 signaling pathway; silencing or overexpression of ANKRD1 modulates SLC7A11 and GPX4 expression and the extent of ferroptosis induced by CaOx crystals.\",\n      \"method\": \"Lentiviral ANKRD1 silencing and overexpression, Western blot for ferroptosis markers (SLC7A11, GPX4, ACSL4), Fe2+ accumulation assay\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, gain- and loss-of-function with Western blot readout only, no direct epistasis experiment\",\n      \"pmids\": [\"36907445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANKRD1 promotes osteogenic differentiation of BMSCs by modulating CAV3 expression through reduction of CAV3 ubiquitination, thereby activating Wnt/β-catenin signaling; CAV3 knockdown abolishes the pro-osteogenic effect of ANKRD1 overexpression.\",\n      \"method\": \"Lentiviral ANKRD1 overexpression and knockdown in BMSCs, ALP activity, osteogenic gene qPCR, Wnt/β-catenin pathway analysis, CAV3 ubiquitination assay, epistasis (CAV3 knockdown rescue)\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay identifies mechanism; epistasis via CAV3 KD validates pathway position; single lab\",\n      \"pmids\": [\"36958710\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ANKRD1/CARP is a stress-inducible, dual-compartment protein that resides in the sarcomeric I-band (bound to titin N2A domain, myopalladin, and calsequestrin-2) and translocates to the nucleus where it acts as a transcriptional co-repressor (of ANF, MMP13, androgen receptor targets) or co-activator (of p53), interacts with ERK1/2 and GATA4 to relay hypertrophic signals, inhibits NF-κB through direct binding to p50, and is rapidly degraded by the 26S proteasome via a PEST-motif-dependent mechanism; its mRNA stability is post-transcriptionally regulated by the RNA-binding protein RBMS1 during senescence, its nuclear import is controlled by a nuclear localization signal, and in non-muscle contexts it drives cancer-associated fibroblast activation by co-operating with AP-1 transcription factors, promotes ferroptosis by facilitating TRIM25-mediated K63-ubiquitination and degradation of ACSL3, and regulates cell motility through lamellipodia formation involving talin-1 and the integrin/FAK pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ANKRD1/CARP is a stress-inducible, dual-compartment protein that couples the mechanical state of the sarcomere to gene expression, with broader roles in tissue injury, fibroblast activation, and cell motility [#0, #6]. In striated muscle it resides at the sarcomeric I-band through direct binding to the titin N2A domain and myopalladin, and to cardiac calsequestrin-2, with disease-associated mutations altering these interactions and CARP localization [#0, #8]. ANKRD1 translocates to the nucleus where it acts as a context-dependent transcriptional coregulator: it represses ANF, MMP13/MMP10 (via the AP-1 site, opposing c-Jun binding), and androgen-receptor target genes, while co-activating p53 to induce TP53, BAX and CDKN1A and destabilize MDM2 [#10, #12, #15]. It relays hypertrophic signaling as part of an ANKRD1/ERK1/2/GATA4 complex that translocates to the nucleus upon adrenergic stimulation, with Ankrd1 required for phenylephrine-induced but not pressure-overload hypertrophy, and it feeds back on inflammatory signaling by binding the NF-\\u03baB p50 subunit to inhibit TNF\\u03b1-induced transcription [#6, #9]. ANKRD1 abundance is tightly controlled by 26S proteasome-mediated degradation through a PEST motif and additional degrons, while its mRNA is stabilized by the RNA-binding protein RBMS1 during senescence [#4, #25, #23]. Beyond muscle, ANKRD1 drives cancer-associated fibroblast activation under androgen-receptor negative control by promoting c-JUN/FOS (AP-1) association at effector gene loci, regulates cell spreading, migration and lamellipodia formation through talin-1 and the integrin/FAK pathway, and promotes ferroptosis by facilitating TRIM25-mediated K63-ubiquitination and degradation of ACSL3 [#20, #11, #22, #19]. Compartment-specific studies indicate nuclear ANKRD1 exacerbates pathological cardiac remodeling whereas cytosolic ANKRD1 is cardioprotective, and blocking its nuclear import improves cardiac function [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that ANKRD1 has a direct structural partner in the cardiac calcium-handling apparatus, anchoring it in the heart beyond a purely nuclear role.\",\n      \"evidence\": \"Pull-down, blot-overlay, Co-IP and peptide mapping from heart extracts with immunohistochemistry\",\n      \"pmids\": [\"15698842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the ANKRD1\\u2013CASQ2 interaction for calcium handling not defined\", \"Whether binding is dynamic or constitutive unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked ANKRD1 protein stability to its transcriptional repressor function, showing a disease mutation that stabilizes the protein and enhances repression of the ANF promoter.\",\n      \"evidence\": \"In vitro calpain degradation assay and reporter gene assay in HeLa cells with a TAPVR-associated mutation\",\n      \"pmids\": [\"18273862\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting stability to repression not resolved\", \"Calpain role in vivo not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined ANKRD1 as a node in sarcomeric stretch sensing by mapping cardiomyopathy mutations onto titin/myopalladin and talin-1/FHL2 interactions and onto altered stretch-induced and repressor activity.\",\n      \"evidence\": \"Co-IP and localization in neonatal rat cardiomyocytes, yeast two-hybrid, stretch and reporter/hypertrophy assays with HCM and DCM mutants\",\n      \"pmids\": [\"19608031\", \"19608030\", \"19525294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration that mutant binding changes cause disease in vivo lacking at this stage\", \"Whether stretch directly modulates ANKRD1 conformation untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the proteasome and a PEST motif as the principal control of ANKRD1 turnover, framing it as a rapidly degraded stress-inducible factor.\",\n      \"evidence\": \"Proteasome inhibitor treatment, PEST motif mutagenesis, and pulse-chase analysis\",\n      \"pmids\": [\"19589340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Responsible E3 ligase not identified\", \"Other contributing degrons uncharacterized\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed ANKRD1 in a reciprocal regulatory loop with p53, acting as a co-activator while being a p53 transcriptional target.\",\n      \"evidence\": \"Protein array, in vivo/in vitro Co-IP, and promoter reporter assay\",\n      \"pmids\": [\"20599664\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of p53 co-activation undefined\", \"Physiological context of the loop not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated co-dependence of ANKRD1 and GATA4 for myofilament gene expression and sarcomere integrity, with GATA4 driving the ANKRD1 promoter.\",\n      \"evidence\": \"Reporter assay, siRNA knockdown, adenoviral overexpression and doxorubicin rescue in cardiomyocytes\",\n      \"pmids\": [\"22532871\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ANKRD1 occupancy of myofilament gene promoters not shown\", \"Single-lab in vitro evidence\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed cell-type-specific control of ANKRD1 half-life by the proteasome, explaining short-lived versus stable pools across cardiomyocytes and endothelium.\",\n      \"evidence\": \"Proteasome inhibition and pulse-chase half-life measurement in rat ventricular myocytes and endothelial cells\",\n      \"pmids\": [\"22892129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for cell-type differences in half-life unknown\", \"Density-dependent degradation mechanism unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved that distinct HCM mutations act through different mechanisms\\u2014gain-of-function versus proteasome-driven instability and dominant-negative effects\\u2014directly tying degradation to contractile phenotype.\",\n      \"evidence\": \"AAV gene transfer into engineered heart tissue with contractile analysis and proteasome inhibition\",\n      \"pmids\": [\"23572067\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Patient-level causality not established\", \"How instability translates to relaxation defects mechanistically unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended ANKRD1's repressor role to androgen-receptor signaling in muscle, with testosterone downregulating Ankrd1 and ANKRD1 repressing AR target genes.\",\n      \"evidence\": \"Co-IP and ARE/MAFbx reporter assays with testosterone-regulated gene qPCR in myoblasts\",\n      \"pmids\": [\"23811403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ANKRD1 binds AR target promoters directly not shown\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a transcriptional repression mechanism in which ANKRD1 antagonizes c-Jun at AP-1 sites to silence matrix metalloproteinases, validated in knockout fibroblasts.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, EMSA, ChIP, promoter assays and Ankrd1-null mouse analysis\",\n      \"pmids\": [\"24515436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of the nucleolin interaction unclear\", \"Direct DNA binding versus AP-1 sequestration not fully separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established ANKRD1 as required for fibroblast spreading, migration, collagen contraction and wound healing, demonstrating a non-muscle structural/motility function in vivo.\",\n      \"evidence\": \"Global Ankrd1 KO mouse with migration, 3D gel contraction, adenoviral rescue, and wound/ischemic flap models\",\n      \"pmids\": [\"25452119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular effector linking ANKRD1 to actin organization not pinpointed here\", \"Cell-autonomous versus systemic contribution not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the ANKRD1/ERK1/2/GATA4 signaling complex as the relay for adrenergic hypertrophy, with stimulus-specific requirement for Ankrd1.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, adrenergic stimulation, and Ankrd1 KO mice with PE infusion versus TAC\",\n      \"pmids\": [\"25770146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ANKRD1 selectively couples to PE but not pressure-overload signaling unknown\", \"Direct contacts within the complex not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed ANKRD1 provides feedback inhibition of inflammatory signaling by binding NF-\\u03baB p50 and occupying an NF-\\u03baB site in the ANKRD2 promoter.\",\n      \"evidence\": \"Co-IP, siRNA, NF-\\u03baB reporter and ChIP in C2C12 myoblasts\",\n      \"pmids\": [\"26102030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of p50 binding undefined\", \"In vivo significance of the feedback loop untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected ANKRD1 to catecholamine biosynthesis, with ERK5 inducing it and ANKRD1 stabilizing tyrosine hydroxylase by reducing its ubiquitination.\",\n      \"evidence\": \"Microarray with ERK5/ERK1/2 inhibitors, siRNA, ubiquitination and catecholamine assays in PC12 cells\",\n      \"pmids\": [\"26739108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ANKRD1 reduces TH ubiquitination unknown\", \"Relevance to neuronal physiology in vivo untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Positioned ANKRD1 in the Hippo-RASSF1A axis as a YAP1 target that suppresses cancer cell growth in a p53-dependent manner.\",\n      \"evidence\": \"Reporter/expression assays, Co-IP, and colony formation in cancer cells\",\n      \"pmids\": [\"29179447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ANKRD1 regulation of MDM2 stability not mechanistically defined\", \"Tumor-context specificity unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed gain of ANKRD1 in myocardium causes developmental and diastolic cardiac defects, reinforcing dose- and compartment-sensitive function and dynamic nucleo-sarcomeric localization.\",\n      \"evidence\": \"Myocardium-specific transgenic mice with histology, hemodynamics, myofibrillar assays and transcriptional profiling\",\n      \"pmids\": [\"31688894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for nuclear versus sarcomeric partitioning not defined\", \"Link between titin gene changes and dysfunction not mechanistically closed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Began to link ANKRD1 to ferroptosis through p53/SLC7A11/GPX4 in renal tubular cells.\",\n      \"evidence\": \"Lentiviral silencing/overexpression with Western blot of ferroptosis markers and Fe2+ assay in HK-2 cells\",\n      \"pmids\": [\"36907445\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct epistasis experiment\\u2014pathway position inferred from marker changes only\", \"Single-lab Western-blot readout\", \"Direct ANKRD1 target in this axis not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Implicated ANKRD1 in osteogenic differentiation via CAV3 deubiquitination and Wnt/\\u03b2-catenin activation.\",\n      \"evidence\": \"Lentiviral manipulation in BMSCs with ubiquitination assay and CAV3-knockdown epistasis\",\n      \"pmids\": [\"36958710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ANKRD1 reduces CAV3 ubiquitination unknown\", \"In vivo bone phenotype untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined ANKRD1 as an AR-repressed mesenchymal coregulator driving cancer-associated fibroblast activation through AP-1 (c-JUN/FOS) cooperation.\",\n      \"evidence\": \"ChIP, AP-1 Co-IP, knockdown, AR manipulation and orthotopic skin cancer model\",\n      \"pmids\": [\"38310103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ANKRD1 directly contacts AP-1 components mapped only by Co-IP\", \"Generalizability beyond skin tumor context unestablished\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed ANKRD1 promotes ferroptosis by enabling TRIM25-mediated K63-ubiquitination and degradation of ACSL3 in renal ischemia-reperfusion.\",\n      \"evidence\": \"IP-MS interactome, Co-IP, proximity ligation, ubiquitination assay and rAAV9 knockdown in vivo\",\n      \"pmids\": [\"39285846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ANKRD1 facilitates TRIM25 activity mechanistically unclear\", \"Relationship to the p53/SLC7A11 ferroptosis route not reconciled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated opposing roles of nuclear versus cytosolic ANKRD1 in heart failure and identified AGO2-driven transcription and NLS-blocking peptides as therapeutic levers.\",\n      \"evidence\": \"Compartment-specific AAV9 overexpression, TAC model, reporter assays and pharmacological intervention (ivermectin, ANPep)\",\n      \"pmids\": [\"38475992\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular signal partitioning ANKRD1 between compartments not defined\", \"Durability/safety of import blockade untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected ANKRD1 to integrin/FAK-based motility and myoblast fate via transcriptional repression of integrin genes and lamellipodial talin-1 colocalization.\",\n      \"evidence\": \"siRNA/overexpression, RNA-seq, Itga6 reporter, FAK phosphorylation, and immunofluorescence co-localization in myoblasts and renal carcinoma cells\",\n      \"pmids\": [\"38988048\", \"40362467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether nuclear repression and lamellipodial localization are the same pool unclear\", \"Direct ANKRD1\\u2013talin-1 binding not biochemically resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed ANKRD1 regulates cardiomyocyte cell cycle and regeneration through cyclin D1.\",\n      \"evidence\": \"Cardiomyocyte-specific knockdown/overexpression in neonatal apical resection and adult MI models with cyclin D1 analysis\",\n      \"pmids\": [\"39299480\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct link between ANKRD1 and cyclin D1 regulation not mechanistically defined\", \"Translatability to human cardiac repair untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified post-transcriptional control of ANKRD1 by RBMS1-mediated mRNA stabilization during senescence.\",\n      \"evidence\": \"ASO pulldown-MS, RIP, mRNA half-life, RBMS1 manipulation and heterologous reporter\",\n      \"pmids\": [\"38769646\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional output of senescence-associated ANKRD1 induction not defined\", \"RBMS1 binding site fine-mapping incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown what molecular switch governs ANKRD1 partitioning between its sarcomeric/cytosolic structural role and its nuclear transcriptional role, and which E3 ligase enforces its PEST-dependent turnover.\",\n      \"evidence\": \"No timeline discovery defines the compartment-switch signal or the responsible degradation machinery\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Compartment-partitioning signal unidentified\", \"E3 ligase for ANKRD1 degradation unknown\", \"Unifying logic across muscle, fibroblast, cancer and ferroptosis roles unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 10, 12, 20, 21]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 8, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 16, 19]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 10, 17, 18]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 8, 17, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 12, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 25, 19]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [0, 7, 17]}\n    ],\n    \"complexes\": [\n      \"ANKRD1/ERK1/2/GATA4 sarcomeric signaling complex\"\n    ],\n    \"partners\": [\n      \"TTN\",\n      \"MYPN\",\n      \"CASQ2\",\n      \"TLN1\",\n      \"GATA4\",\n      \"TP53\",\n      \"NFKB1\",\n      \"TRIM25\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}